How well can you actually predict which non-muscle-invasive bladder cancer patients will progress?

Editorial

Richard J Sylvester. Eur Urol. 2011 Sep.

. 2011 Sep;60(3):431-3; discussion 433-4.

doi: 10.1016/j.eururo.2011.06.001. Epub 2011 Jun 12.

No abstract available

Comment on

The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables.
Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Piñeiro L, Ojea A, Portillo J, Montesinos M, Gonzalez M, Pertusa C, Rodriguez-Molina J, Camacho JE, Rabadan M, Astobieta A, Isorna S, Muntañola P, Gimeno A, Blas M, Martinez-Piñeiro JA; Club Urológico Español de Tratamiento Oncológico. Fernandez-Gomez J, et al. Eur Urol. 2011 Sep;60(3):423-30. doi: 10.1016/j.eururo.2011.05.033. Epub 2011 May 25. Eur Urol. 2011. PMID: 21621906